Volume 2, Issue 1
Prescription Drug Policy
Ongoing debates in the pharmaceutical sector about intellectual property, pricing and reimbursement, and public research investments have a common denominator: he pursuit of innovation. However, there is little clarity about what constitutes a true pharmaceutical innovation, and as a result there is confusion about what kind of new products should be pursued, protected and encouraged through health policy and clinical practice. If the concept of pharmaceutical innovation can be clarified, then it may become easier for health policy-makers and practitioners to evaluate, adopt and procure products in ways that appropriately recognize, encourage and give priority to truly valuable pharmaceutical innovations.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License.
Morgan, S., Lopert, R., Greyson, D. (2008). Toward a definition of pharmaceutical innovation. Open Medicine, 2(1), e4-7.